Monthly Archives: May 2019

EDOR® Test Identifies Patients with a Higher Risk of Depression Relapse

Emotra has previously announced that new research results have indicated new application areas for Emotra’s method, EDOR. These areas open new possibilities for widening the method’s use in clinical practice. We can now reveal that the application in question concerns the fact that hyporeactive patients run a higher risk of depression relapse than normally reactive [...]

By | May 9th, 2019|INVESTORS|Comments Off on EDOR® Test Identifies Patients with a Higher Risk of Depression Relapse

Emotra is granted a patent in the USA

The US will be one of Emotra’s priority markets in the future. We have earlier announced that the Company has applied for patents in the EU, USA, Canada and Japan and patents have been granted in Sweden and Japan. The US patent office has now informed us that Emotra’s American patent application “US Application No. [...]

By | May 3rd, 2019|INVESTORS|Comments Off on Emotra is granted a patent in the USA